NCT02690870

Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF

Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: Female
• Age: 37 Years – 42 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this prospective cohort study is to compare IVF outcome between tamoxifen and clomiphene citrate in mild stimulation.

Detailed description

The reported prevalence of poor ovarian responders amongst patients undergoing IVF-ET is 9%-24%, and morbidity must be higher nowadays. For these women, Mild stimulation has been an important ovulation induction protocol. Clomiphene citrate(CC) and tamoxifen(TMX) are commonly used in mild stimulation protocol. It's reported that CC has adverse effect on growth of endrometrium and results in thin endrometrium(≤7mm) which maybe affect pregnancy rate. However, TMX has estrogen-like effect on the endrometrium that may be helpful to increase endormetrial thickness. The reported results about comparing CC with TMX showed that they had similar ovulation rate. Prospective study is necessary to confirm whether TMX is superior to CC on the IVF outcome.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	Tamoxifen	Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
DRUG	Clomiphene	Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.

Timeline

• Start date: 2017-01-01
• Primary completion: 2018-05-01
• Completion: 2019-03-01
• First posted: 2016-02-24
• Last updated: 2016-02-25